Nektar Therapeutics (NKTR)

NASDAQ: NKTR · IEX Real-Time Price · USD
0.780
+0.070 (9.86%)
At close: Mar 1, 2024, 4:00 PM
0.779
-0.001 (-0.13%)
After-hours: Mar 1, 2024, 7:59 PM EST
9.86%
Market Cap 148.80M
Revenue (ttm) 88.26M
Net Income (ttm) -293.67M
Shares Out 190.77M
EPS (ttm) -1.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,855,086
Open 0.715
Previous Close 0.710
Day's Range 0.715 - 0.799
52-Week Range 0.410 - 1.600
Beta 0.78
Analysts Hold
Price Target 3.25 (+316.67%)
Earnings Date Mar 4, 2024

About NKTR

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma an... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 3, 1994
Employees 216
Stock Exchange NASDAQ
Ticker Symbol NKTR
Full Company Profile

Financial Performance

In 2022, NKTR's revenue was $92.06 million, a decrease of -9.67% compared to the previous year's $101.91 million. Losses were -$368.20 million, -29.71% less than in 2021.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for NKTR stock is "Hold." The 12-month stock price forecast is $3.25, which is an increase of 316.67% from the latest price.

Price Target
$3.25
(316.67% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference

SAN FRANCISCO , Feb. 27, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on Tuesday, Ma...

5 days ago - PRNewsWire

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets

SAN FRANCISCO , Feb. 26, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4, 2024, a...

6 days ago - PRNewsWire

Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA

SAN FRANCISCO , Jan. 3, 2024 /PRNewswire/ -- Nektar (Nasdaq: NKTR) management is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Janua...

2 months ago - PRNewsWire

Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting

– NKTR-255 Combination Expanded NK Cells and Enhanced ADCC Against Rituximab-Resistant Burkitt Lymphoma (BL) Cells – SAN FRANCISCO , Dec. 11, 2023 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) ann...

2 months ago - PRNewsWire

Nektar Therapeutics Reports Third Quarter 2023 Financial Results

SAN FRANCISCO , Nov. 7, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2023. Cash and investments in marketable secu...

4 months ago - PRNewsWire

Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets

SAN FRANCISCO , Oct. 31, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on Tuesday, November 7, 2023, after the close of U.S.-ba...

4 months ago - PRNewsWire

Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress

– Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rapid Onset of Action and Continuing Benefit for 36 Weeks After 12-Week Treatment Period – – New Data Presented Show ...

5 months ago - PRNewsWire

Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy

– Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be Presented in Late-Breaking Oral Presentation – SAN FRANCISCO , Oct. 2, 2023 /PRNewswire/ -- Nekt...

5 months ago - PRNewsWire

Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer

SAN FRANCISCO , Sept. 27, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group Inc. ("CBM...

5 months ago - PRNewsWire

Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

New Statistically Significant Results Reported for Clinical Efficacy Endpoints of BSA, DLQI and POEM from Phase 1b Study New Phase 2a Study Also Being Planned for Rezpegaldesleukin in Alopecia Areata ...

6 months ago - PRNewsWire

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th

SAN FRANCISCO , Sept. 6, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event on Wednesday, September 13, 2023 at 11:00 a.m.

6 months ago - PRNewsWire

Nektar Therapeutics Reports Second Quarter 2023 Financial Results

SAN FRANCISCO , Aug. 8, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2023. Cash and investments in marketable securiti...

7 months ago - PRNewsWire

Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment

Nektar Therapeutics on Monday sued Eli Lilly , accusing the drugmaker of undermining the prospects for Rezpeg, which Nektar was developing as a treatment for various autoimmune diseases.

Other symbols: LLY
7 months ago - Reuters

Nektar Therapeutics' stock jumps premarket after it says data presented by Eli Lilly for a skin treatment was incorrectly calculated

Nektar Therapeutics' stock NKTR, +3.14% jumped 12.7% in premarket trade Monday, after the company said that efficacy data previously generated by its former partner Eli Lilly & Co. LLY, +0.07% for its...

Other symbols: LLY
7 months ago - Market Watch

Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company

EASI-Related and PASI-Related Clinical Efficacy Endpoints in Atopic Dermatitis and Psoriasis Studies Were Incorrectly Calculated by Lilly and Were Reported Erroneously at EADV 2022 SAN FRANCISCO , Aug...

7 months ago - PRNewsWire

Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets

SAN FRANCISCO , Aug. 1, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2023 on Tuesday, August 8, 2023, after the close of U.S.-base...

7 months ago - PRNewsWire

Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference

SAN FRANCISCO , June 12, 2023 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 44th Annual Glo...

9 months ago - PRNewsWire

Nektar Therapeutics Reports First Quarter 2023 Financial Results

SAN FRANCISCO , May 9, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2023. Cash and investments in marketable securitie...

10 months ago - PRNewsWire

Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development

Company plans to move REZPEG forward into Phase 2 clinical study in atopic dermatitis SAN FRANCISCO , April 27, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will be ...

11 months ago - PRNewsWire

Nektar stock pops as more than half of San Francisco office loses jobs, new CFO appointed

Nektar Therapeutics shares rallied late Monday after the biotech drug maker said it was cutting staff by 60% in San Francisco, where the company is based, and shifting its focus to immunology drugs in...

11 months ago - Market Watch

Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan

Nektar Therapeutics (Nasdaq: NKTR) today announced a strategic reprioritization and cost restructuring plan that includes a new pipeline focus on immunology, as well as several cost reduction initiati...

11 months ago - PRNewsWire

Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank

SAN FRANCISCO , March 11, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today issued a statement confirming that it does not have any accounts at Silicon Valley Bank, and it does not hold an...

1 year ago - PRNewsWire

Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results

SAN FRANCISCO , Feb. 28, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2022. Cash and investments in ...

1 year ago - PRNewsWire

Nektar stock drops more than 30% after study involving lupus treatment will not go forward

Shares of Nektar Therapeutics NKTR, -1.66% plunged more than 30% in the extended session Thursday after the biopharma company reported that a study did not meet goals and that partner Eli Lilly & Co. ...

1 year ago - Market Watch

Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus

Improvement in SLEDAI-2K score observed as compared to placebo, although study did not meet primary endpoint Clinically meaningful improvements observed as compared to placebo across secondary endpoin...

1 year ago - PRNewsWire